168 related articles for article (PubMed ID: 31204415)
1. Serological Assessment of the Quality of Wound Healing Processes in Crohn's Disease.
Sun S; Karsdal MA; Mortensen JH; Luo Y; Kjeldsen J; Krag A; Jensen MD; Bay-Jensen AC; Manon-Jensen T
J Gastrointestin Liver Dis; 2019 Jun; 28():175-182. PubMed ID: 31204415
[TBL] [Abstract][Full Text] [Related]
2. Assessment of Crohn's Disease Activity: Magnetic Resonance Enterography in Comparison with Clinical and Endoscopic Evaluations.
Minordi LM; Larosa L; Papa A; Bordonaro V; Lopetuso L; Holleran G; Gasbarrini A; Manfredi R
J Gastrointestin Liver Dis; 2019 Jun; 28():213-224. PubMed ID: 31204402
[TBL] [Abstract][Full Text] [Related]
3. Impaired Intestinal Permeability Contributes to Ongoing Bowel Symptoms in Patients With Inflammatory Bowel Disease and Mucosal Healing.
Chang J; Leong RW; Wasinger VC; Ip M; Yang M; Phan TG
Gastroenterology; 2017 Sep; 153(3):723-731.e1. PubMed ID: 28601482
[TBL] [Abstract][Full Text] [Related]
4. Reduced plasma fibrin clot permeability and susceptibility to lysis in patients with inflammatory bowel disease: a novel prothrombotic mechanism.
Owczarek D; Cibor D; Sałapa K; Głowacki MK; Mach T; Undas A
Inflamm Bowel Dis; 2013 Nov; 19(12):2616-24. PubMed ID: 24108112
[TBL] [Abstract][Full Text] [Related]
5. Circulating D dimer in inflammatory bowel disease.
Biancone L; Scopinaro F; Maletta M; Monteleone G; Luzza F; Banci M; Mercantini P; Renda T; Pallone F
Ital J Gastroenterol; 1994 Apr; 26(3):116-20. PubMed ID: 8061337
[TBL] [Abstract][Full Text] [Related]
6. Development of an in vitro fibrin clot model to evaluate fibrinolytic agents for wound care application.
Viennet C; Laurensou C; Goydadin AC; Faivre B; Muret P; Humbert P
J Wound Care; 2014 Feb; 23(2):66-7, 70, 72. PubMed ID: 24526082
[TBL] [Abstract][Full Text] [Related]
7. Relationship between fibrinopeptide A and fibrinogen/fibrin fragment E in thromboembolism, DIC and various non-thromboembolic diseases.
Mombelli G; Monotti R; Haeberli A; Straub PW
Thromb Haemost; 1987 Aug; 58(2):758-63. PubMed ID: 3672428
[TBL] [Abstract][Full Text] [Related]
8. Serum Neutrophil Gelatinase B-associated Lipocalin and Matrix Metalloproteinase-9 Complex as a Surrogate Marker for Mucosal Healing in Patients with Crohn's Disease.
de Bruyn M; Arijs I; De Hertogh G; Ferrante M; Van Assche G; Rutgeerts P; Vermeire S; Opdenakker G
J Crohns Colitis; 2015 Dec; 9(12):1079-87. PubMed ID: 26351381
[TBL] [Abstract][Full Text] [Related]
9. Severity of peripheral atherosclerosis is associated with fibrinogen and degradation of cross-linked fibrin.
Lassila R; Peltonen S; Lepäntalo M; Saarinen O; Kauhanen P; Manninen V
Arterioscler Thromb; 1993 Dec; 13(12):1738-42. PubMed ID: 8241093
[TBL] [Abstract][Full Text] [Related]
10. Sequence of release of fibrinopeptide A from fibrinogen molecules by thrombin or Atroxin.
Meh DA; Siebenlist KR; Bergtrom G; Mosesson MW
J Lab Clin Med; 1995 Mar; 125(3):384-91. PubMed ID: 7897305
[TBL] [Abstract][Full Text] [Related]
11. Validity of enzyme-linked immunosorbent assays of cross-linked fibrin degradation products as a measure of clot lysis.
Eisenberg PR; Jaffe AS; Stump DC; Collen D; Bovill EG
Circulation; 1990 Oct; 82(4):1159-68. PubMed ID: 2119264
[TBL] [Abstract][Full Text] [Related]
12. Pretreatment plasma levels of fibrinopeptide-A (FPA), D-dimer (DD), and von Willebrand factor (vWF) in patients with ovarian carcinoma.
Gadducci A; Baicchi U; Marrai R; Del Bravo B; Fosella PV; Facchini V
Gynecol Oncol; 1994 Jun; 53(3):352-6. PubMed ID: 8206409
[TBL] [Abstract][Full Text] [Related]
13. Degradation of fibrinogen and cross-linked fibrin by human neutrophil elastase generates D-like fragments detected by ELISA but not latex D-dimer test.
Bach-Gansmo ET; Godal HC; Skjønsberg OH
Thromb Res; 1998 Nov; 92(3):125-34. PubMed ID: 9806364
[TBL] [Abstract][Full Text] [Related]
14. Thrombin binds to soluble fibrin degradation products where it is protected from inhibition by heparin-antithrombin but susceptible to inactivation by antithrombin-independent inhibitors.
Weitz JI; Leslie B; Hudoba M
Circulation; 1998 Feb; 97(6):544-52. PubMed ID: 9494024
[TBL] [Abstract][Full Text] [Related]
15. Effects of long-term treatment with warfarin on fibrinogen, FPA, TAT, and D-dimer in patients with coronary artery disease.
Eritsland J; Seljeflot I; Arnesen H; Smith P; Westvik AB
Thromb Res; 1992 Apr; 66(1):55-60. PubMed ID: 1412183
[TBL] [Abstract][Full Text] [Related]
16. Fibrinogen, fibrin(ogen) degradation products and fibrinopeptide A in pleural effusions. High turnover of fibrinogen in pleurisy.
Widström O; Kockum C; Nilsson BS
Scand J Respir Dis; 1978 Aug; 59(4):210-5. PubMed ID: 694476
[TBL] [Abstract][Full Text] [Related]
17. Increased markers of thrombogenesis in chronic atrial fibrillation: effects of warfarin treatment.
Lip GY; Lowe GD; Rumley A; Dunn FG
Br Heart J; 1995 Jun; 73(6):527-33. PubMed ID: 7626351
[TBL] [Abstract][Full Text] [Related]
18. Plasmatic parameters of fibrin formation and degradation in cancer patients: correlation between fibrinopeptide A and D-dimer.
Sagripanti A; Carpi A; Baicchi U; Grassi B
Biomed Pharmacother; 1993; 47(6-7):235-9. PubMed ID: 8061250
[TBL] [Abstract][Full Text] [Related]
19. Characterization of the fibrin polymer structure that accelerates thrombin cleavage of plasma factor XIII.
Greenberg CS; Achyuthan KE; Rajagopalan S; Pizzo SV
Arch Biochem Biophys; 1988 Apr; 262(1):142-8. PubMed ID: 2895608
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of Early Atherosclerosis Markers in Patients with Inflammatory Bowel Disease.
Üstün Y; Kilincalp S; Çoban Ş; Coşkun Y; Yüksel İ; Ongun A; Soykan İ; Bektaş M; Törüner M; Çetinkaya H; Örmeci N
Med Sci Monit; 2016 Oct; 22():3943-3950. PubMed ID: 27773920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
